Connect with us

Medical Devices

OraSure and the Will Rodgers Liver Health Foundation to Heighten Awareness Around the Importance of Hepatitis C Testing

Published

on

Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status

BETHLEHEM, Pa. and HUNTERSVILLE, N.C., June 14, 2021 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it is collaborating with the Will Rodgers Liver Health Foundation to increase awareness around the role Hepatitis C (HCV) plays in chronic liver disease and promoting testing services for HCV within the United States. The U.S. Centers for Disease Control estimates that approximately 2.4 million individuals in the United States have HCV, and over half of these individuals currently don’t know their disease status. Left untreated, HCV often leads to liver cirrhosis, liver cancer, and liver failure. These outcomes are preventable given new antiviral drugs that can effectively cure patients, but early diagnosis through increased testing is vital to eradicating this disease. According to data from the National Institutes of Health, healthcare costs associated with chronic HCV infection are $6.5 billion per year in the United States today and continue to rise, representing a substantial burden on our healthcare system.

“As a liver disease patient who endured Primary Sclerosing Cholangitis as a child, and through friends affected by HCV, I know the toll liver disease can have on your body, especially if it’s left untreated,” Will Rodgers, NASCAR driver, said. “This terrible disease, which affects so many in the United States, is a significant strain on our healthcare system, and could be eradicated through broad scale testing initiatives. “I’m very proud to work with OraSure to drive increased awareness around HCV and provide testing services to underserved communities across the country.”

“At OraSure, we take public health seriously and have played a significant role in combating diseases such as HCV, HIV, and COVID-19 on a global basis. Our OraQuick® HCV rapid antibody test is designed to be extremely simple to use, highly accurate and provides a result within 20 minutes, while simultaneously being cost effective,” said OraSure President and CEO Stephen Tang, Ph.D. “As a company, we are extremely proud to collaborate with the Will Rodgers Liver Health Foundation to drive greater awareness around the importance of individuals knowing their HCV status. A simple test can save a life.”

As a 3-year-old child, Rodgers was diagnosed with Primary Sclerosing Cholangitis, an extremely rare, chronic liver disease. While the disease has no present cure, his disease abated after two years of treatment, to the delight of his physicians and family. Following the end of his treatments, Rodgers’ racing journey began to take shape.

As a first generation race car driver, Rodgers was introduced to go-kart racing at the age of eight and within 18 months was the reigning Hawai’i state champion and track record holder in Maui. From there, Rodgers became a regional champion in motocross, a stadium series champion in off-road UTVS and a 2015 West Coast NASA champion in sports car racing. In 2016, Rodgers became the winningest driver in the Pirelli World Challenge Pro B Spec class. These personal achievements paved the way for his current career in NASCAR, where he has gone on to become a winner in both the ARCA Menards Series East (2017-2018) and the ARCA Menards Series West (2018).

Inspired by Will Rodgers personal endurance with liver disease, the Will Rodgers Liver Health Foundation was formed in 2020 to fill gaps for those affected with liver health issues by providing education, testing resources, and a link to care. The Will Rodgers Liver Health Foundation’s vision is to build awareness and provide education of liver disease, remove any barriers for treatment of liver diseases from targeted demographics, provide link-to-care in targeted communities, and eliminate the negative stigma surrounding liver disease.

The foundation’s effort, driven by Rodgers, is culminating into his overall vision — a brand new philanthropic campaign to raise awareness for HCV — RaceToEndHepC.com.

“A major element of the Race To End Hep C initiative is the at-track and in-community activation space. It’s important to reach the communities affected by HCV, in person, to communicate the importance of education, testing and treatment. Together, with our supporting partners, we’ll be providing a step-by-step process for any individuals wanting to learn more about HCV and how we’re Racing to End it.”

The Will Rodgers Liver Health Foundation will provide an interactive environment at race events and select community locations to encourage liver health. Through his collaboration with OraSure, individuals will be provided with free HCV testing, which allows you to receive your results in minutes with a simple finger prick, educational materials and resources to take the next step for those with liver health needs.

To find a community event near you, visit www.RaceToEndHepC.com.

About HCV and the OraQuick® HCV Rapid Antigen Test
According to the CDC, HCV is the most common chronic blood-borne infection in the United States, with approximately 2.4 million people infected. It is estimated that one in 30 Baby Boomers (adults born between 1945 and 1965) have chronic Hepatitis C and over half of the people infected with HCV in the United States are unaware of their infection. The CDC, the U.S. Preventive Services Task Force (USPSTF), and the American Association for the Study of Liver Diseases (AASLD) have all issued guidance that recommends HCV testing for at-risk individuals including all Baby Boomers.

OraQuick® HCV is the first and only FDA-approved and CLIA-waived point of care test for detection of HCV infection in at-risk individuals. The simple platform enables healthcare providers to deliver a diagnosis based on lab-accurate test results in 20 minutes, using venipuncture or fingerstick blood.

About the Will Rodgers Liver Health Foundation
By uniting the healthcare industry, the Will Rodgers Liver Health Foundation (WRLHF) seeks to build awareness and provide education on liver disease, remove any barriers for treatment of liver diseases for targeted demographics, provide link-to-care in targeted communities, and eliminate negative stigma surrounding liver disease. The WRLHF fills a need for a national, far-reaching campaign, coupled with a true ambassador for liver health. The foundation focuses on consumable education for the public, provides on-site & in-the-field testing and links patients with proper care. Additionally, the WRLHF stands to change the public’s negative perception of liver disease and has a goal to positively change the conversation. For more information on the Will Rodgers Liver Health Foundation, visit www.liverhealth.foundation.

About OraSure Technologies
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

Important Information

This press release contains certain forward-looking statements, including with respect to expected revenues, products, product development activities, regulatory submissions and authorizations and other matters. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to successfully manage and integrate acquisitions of other companies in a manner that complements or leverages our existing business, or otherwise expands or enhances our portfolio of products and our end-to-end service offerings, and the diversion of management’s attention from our ongoing business and regular business responsibilities to effect such integration; the expected economic benefits of acquisitions (and increased returns for our stockholders), including that the anticipated synergies, revenue enhancement strategies and other benefits from the acquisitions may not be fully realized or may take longer to realize than expected and our actual integration costs may exceed our estimates; impact of increased or different risks arising from the acquisition of companies located in foreign countries; ability to market and sell products, whether through our internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; the impact of the novel coronavirus (“COVID-19”) pandemic on our business and our ability to successfully develop new products, validate the expanded use of existing collector products, receive necessary regulatory approvals and authorizations and commercialize such products for COVID-19 testing; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for the Company’s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid or urine testing, collection or other products; market acceptance and uptake of microbiome informatics, microbial genetics technology and related analytics services; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) or other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; impact of contracting with the U.S. government; impact of negative economic conditions; ability to maintain sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2020, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

Media Contact:   Investor Contact:
Jessica O’Brien   Scott Gleason
803-240-5807   SVP Investor Relations & Corp. Comms.
[email protected]   484-425-0588
    [email protected]
     
Will Rodgers Liver Health Foundation Contact:   Media Contact:
Karleen Margenean   Amy Koch
586-839-7417   Sr. Mgr. Corporate Communications
    484-523-1815
    [email protected]

Primary Logo

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/orasure-and-the-will-rodgers-liver-health-foundation-to-heighten-awareness-around-the-importance-of-hepatitis-c-testing/?s=93

Medical Devices

Cartessa Aesthetics’ Innovative Multi-Modality Treatment Leads Demand for Non-Invasive Body Procedures

Published

on

MELVILLE, N.Y., July 28, 2021 /PRNewswire/ — Cartessa Aesthetics recently launched its newest device, PHYSIQ, leading the demand for the latest advancement in body treatments. PHYSIQ is a novel, dual-modality system that offers deep heat to target tissue and electrical muscle stimulation (EMS) to re-educate muscle – all from one device and in one session. An incredibly versatile device, PHYSIQ’s four applicators can be individually adjusted to tailor the energy and modality delivered to one or more body areas. Providers can select EMS or deep heat only or they have the unique ability to deliver both modalities sequentially within one treatment to maximize results and overall comfort. Treatments are hands-free, require no downtime and can be completely customized to meet each patient’s unique body goals.

Cartessa Aesthetics has made a name for itself by working with leading global aesthetic manufacturers to introduce best-in-class devices to the North American market. With PHYSIQ, aesthetic providers and patients have an optimized body treatment distinct from existing technology in the space. 

“Optimizing clinical outcomes while providing best-in-class return on investment to physicians is at the core of Cartessa’s mission statement,” said Gabe Lubin, Cartessa Aesthetics Founder and CEO. “More people are favoring non-invasive procedures, even for treatments that address challenging body aesthetics. Patients want results, but without the pain and downtime that comes with surgery. Being able to offer a more complete patient treatment in a 30-minute session will offer providers a unique competitive advantage in the robust body market.”

The non-invasive body treatment category has erupted in the last decade. From 2011 to 2018 the number of procedures grew four-fold and it is estimated that by 2025, the North American market will hit $1.6 billion growing at an 8% compounded growth rate. PHYSIQ’s low consumable costs, minimal required staff-time and healthy patient demand makes it a premier investment opportunity for aesthetic providers. Sessions range from 24 to 36 minutes and the ability to address multiple body areas with multiple modalities in one session has established PHYSIQ as being truly unique in the body space.

Those interested in PHYSIQ can learn more by visiting www.physiqbody.com or reach out to a Cartessa Aesthetics agent via email at [email protected].

Approximate pricing, $500/session and up. Although results may be noticed after only the first treatment, PHYSIQ is administered in a series of 5 treatments/sessions, 1 treatment every 2 weeks.

About Cartessa Aesthetics, LLC.
Cartessa Aesthetics, LLC sources leading aesthetic medical devices for distribution to dermatologists, plastic surgeons, cosmetic physicians and medical spas. Cartessa selects the most cutting-edge technologies that offer clinically proven efficacy, patient safety, and the best possible investment for patients and professionals. The company’s portfolio includes VirtueRF, Motus AX & Motus AY, Tetra CO2 with CoolPeel and Luxea (all manufactured by DEKA), Subnovii Advanced Plasma Technology and Skinwave.  Cartessa is also the exclusive US partner for Quanta Systems.  

For more information visit: www.cartessaaesthetics.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cartessa-aesthetics-innovative-multi-modality-treatment-leads-demand-for-non-invasive-body-procedures-301343522.html

SOURCE Cartessa Aesthetics

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/cartessa-aesthetics-innovative-multi-modality-treatment-leads-demand-for-non-invasive-body-procedures/?s=93

Continue Reading

Medical Devices

Pixium Vision announces its financial results for H1 2021 and provides a business update

Published

on

PRESS RELEASE

Pixium Vision announcesitsfinancialresults for H1 2021andprovidesabusiness update

  • Cash position at 30 June 2021: €10.1 million
  • PRIMAvera European pivotal study of Prima System ongoing
  • Pixium Vision appointed Offer Nonhoff, an experienced international financial executive
  • Post period event – € 8M PIPE transaction with new US investors extends cash runway to end of 2022

Paris, 27 July 2021 – 7.00 a.m. CET – Pixium Vision (FR0011950641 – PIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for the first half of 2021. The H1 2021 financial statements were approved by Pixium Vision’s Board of Directors at its meeting on 26 July 2021.

Lloyd Diamond, CEO of Pixium Vision, commentedWe are pleasedwith the continued transformation ofPixiumVisionfromaresearchtoacommercialorganization,withanumberofsignificantmilestonesachievedin the first half of 2021. Clinically, we are making good progresswith the PRIMAvera pivotal trial of our PrimaSystem for bionic vision and have closedadditionalfinancing lead by US investors in order to ensure thesuccess ofourclinical programs.”

”The financialresults are based on a solidfinancial position, with €10.1 million in cash at end of June 2021plus an additional €8 millionraised in a successful capital increase, providingfundinguntil end of 2022. Weare nowalso building on oursuccessful interactions with US investors by exploring the possibility of listing ontheNASDAQstockexchange”addedOfferNonhoff,CFOofPixiumVision

H12021 results – Highlights

Incomestatementsummary      
Inthousandsofeuros H12021 H12020 Change
Operatingrevenue 1,801.0 1,250.7 +44.6%
Currentoperatingexpenses (6,636.8) (4,524.4) +46.7%
Research and Development (3,692.0) (2,860.1) +29.1 %
General and administrative expenses (2,944.8) (1,664.3) +76.9 %
Operatingloss (4,835.8) (3,273.7) +47.7%
Netloss for theperiod (5,551.3) (3,802.3) +46.0%
Netearningsper share (0.12) (0.15)  

Page 1 / 5

Statementofcashflowssummary    
Inthousandsofeuros H12021 H12020
Openingcashand cashequivalents 10,566.0 6,791.5
(Decrease)/Increasein cashposition (434.5) (1,787.1)
O/Wnetcashflowsfromoperating activities (6,115.4) (2,787.8)
O/Wnetcashflowsfrominvestmentactivities (32.0) 163.7
O/Wnetcashflowsfromfinancingactivities 5,712.9 837.0
Closingcashandcash equivalents 10,131.4 5,004.4

UpdateonPixiumVision’s business

Pixium Vision continued to make significant clinical and business progress in H1 2021, including implanting the first patients in the European PRIMAvera pivotal trial evaluating the safety and efficacy of the Prima System in patients affected by dry Age-related Macular Degeneration (AMD).

The company also reported extremely compelling results from the French feasibility study, demonstrating that thanks to the new transparent Prima glasses, patients could simultaneously use prosthetic central vision generated with the Prima System and their remaining peripheral vision. Indeed, using electronic magnification, patients gained visual acuity in the range of 20/63-20/98, greatly exceeding the threshold of legal blindness (20/200).

Pixium Vision remained focused on delivering on its strategy, despite the termination of the planned business combination with Second Sight. Pixium Vision announced an ambitious plan to build on traction gained with US investors and strengthen its presence in the important US market, and hiring a leading US investment bank to contemplate a potential US NASDAQ listing.

AnalysisofH12021 results

Operating revenue amounted to €1.8 million and is comprised essentially of a Research Tax Credit (CIR) in the amount of €0.9 million and €0.8 million for contractual indemnities paid by Second Sight Medical Product Inc. (SSMP). These indemnities were paid following the unilateral termination of the MOU between the two companies concluded on 5 January 2021 by SSMP.

CurrentResearch and Development (R&D) expenses totalled €3.69 million, compared to €2.86 million the previous year. During the first half of 2021, Pixium Vision strengthened its clinical team and opened several centres in Europe as part of its PRIMAvera study. In addition, the Group continued to develop and manufacture its Prima bionic vision system to ensure the progress of its ongoing clinical studies.

Currentgeneral and administrative (G&A) expenses totalled €2.94 million in H1 2021, compared to €1.66 million in H1 2020. General and administrative expenses increased by 76.9% in H1 2021, mainly due to the costs the Group incurred for legal services in preparation for its business combination with the US company Second Sight Medical Products, Inc.

In H1 2021, the Group did not recognise any marketingandsalesexpenses.

Operatingresult presented a loss of €4.84 million, which is higher than in H1 2020 (€3.27 million). Netresult was a loss of €5.55 million (compared to a loss of €3.80 million in H1 2020). The loss per share is €0.12 down over the €0.15 loss per shares reported in H1 2020.

Net cash outflow from operating activities increased in H1 2021 to €6.1 million, compared to €2.8 million in H1 2020. The increase in net cash outflow reflects the initiation of the PRIMAvera study, the continuation of the US feasibility study, as well as the spending associated with the preparation of the business combination

with Second Sight Medical Products, Inc. The basis for comparison in H1 2020 was also particularly low due to COVID-19 related slow-down in operations over the course of 2020.

Netcashflowsfromfinancingactivities totalled €5.7 million in H1 2021. This reflect primarily the drawdown of 5 ORNAN tranches for a total of €6.25 million in gross proceeds under its agreement with ESGO. Following the drawdown of the last tranche on 12 May 2021, there is no longer any outstanding warrants as the entire 10 million financing has been drawn.

Pixium Vision ended H1 2021 with a net cash position of €10.1 million, compared to €5.0 million a year earlier.

Post-period, on July 13, 2021, Pixium Vision increased its cash balance through a capital increase of approximately €8.0 million in Gross proceeds and approximately €7.4 million in net proceeds.

Contacts

ABOUTPIXIUMVISION

Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period.

Pixium Vision is conducting clinical feasibility studies of its Prima system, its miniaturised wireless sub-retinal implant, in patients who have lost their sight due to retinal degeneration associated with the dry form of Age- Related Macular Degeneration (AMD). Pixium Vision works closely with world-renown academic partners, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, and UPMC in Pittsburgh, USA. The company is EN ISO 13485 certified. Pixium Vision has been qualified as an “Innovative Company” by Bpifrance.

For more information: http://www.pixium-vision.com/fr
Follow us on @PixiumVision;www.facebook.com/pixiumvision
w.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext Growth Paris. ISIN: FR0011950641; Mnemonic: ALPIX
Pixium Vision is included in the Euronext GROWTH ALLSHARE index Pixium Vision shares are eligible for the French PEA-PME and FCPI investment vehicles.

Disclaimer

This press release, implicitly or expressly, contains certain forward-lookingstatements concerning PixiumVision and its business. Suchstatementsinvolveknown and unknownrisks, uncertainties and otherfactorsthatmaycausetheactualresults,financialconditions,performanceorachievementsofPixiumVisiontobe

materiallydifferent from the results, financial conditions, performance or achievementsexpressed or impliedby suchforward-lookingstatements. Pixium Vision issues thispress release as at this date and does notundertaketoupdateanyforward-lookingstatementscontainedherein,whetherinresponsetonewinformation,future events or otherwise. For a description of the risks and uncertainties that could cause the actual results, financial conditions, performance or achievements of Pixium Vision to differ from those contained in the forward-looking statements, please refer to section 3 “Risk Factors” of the Company’s reference document, which was filed with the AutoritédesMarchésFinanciers under number D.20-0350 on 24 April 2020, and which can be viewed on the websites of the Autorité des Marchés Financiers – “AMF” (www.amf-france.org) and Pixium Vision (www.pixium-vision.com).

Attachment

Primary Logo

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/pixium-vision-announces-its-financial-results-for-h1-2021-and-provides-a-business-update/?s=93

Continue Reading

Medical Devices

MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment

Published

on

SHANGHAI, July 27, 2021 /PRNewswire/ — MicroPort Scientific Corporation (“MicroPort®“) announced that MicroPort Cardiac Rhythm Management Limited (“MicroPort® CRM“), which is MicroPort®‘s subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million. Hillhouse Capital Group and MicroPort® will co-lead the Series C investment and will invest US$20 million and US$47 million, respectively. Six new investors that will invest an additional US$83 million in capital include CICC, Country Garden Venture Capital (CGVC), YongRong Asset Management Ltd., L Squared Private Management, E Fund Management Co. Ltd., and Wanhui Capital. After the completion of this transaction, MicroPort® will continue to be the majority shareholder of MicroPort® CRM. The financing is expected to close in early August 2021, subject to customary closing conditions.

Originally acquired in April 2018, MicroPort® CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure through cardiac resynchronization therapy (CRT). Headquartered in Clamart (outside Paris) France, MicroPort® CRM has dedicated R&D teams in Clamart and Shanghai, and world class manufacturing facilities in France, Italy, the Dominican Republic and China. Currently MicroPort® CRM employs approximately 1,100 employees globally.

For decades, MicroPort® CRM has been at the forefront of innovation in the CRM industry and has implanted more than two million patients worldwide with its pacemakers and defibrillators. The company is known for its cutting-edge technology, small, long-lasting devices, and the most advanced therapeutic solutions. In 2015, MicroPort® CRM launched the PLATINIUM™ family of implantable defibrillators, which has the longest projected service life of any implantable defibrillator on the market, reducing the risks associated to repeated replacements. In 2019, the company launched ENO™, TEO™ and OTO™, the world’s smallest family of pacemakers, 1.5T and 3T MRI conditional. In 2021, MicroPort® CRM launched a new family of pacemakers, ALIZEA™ and BOREA™, featuring Bluetooth® technology and wireless remote monitoring. In its product pipeline, MicroPort® CRM plans to launch a complete new line of defibrillator systems, including devices and leads, 1.5T and 3T MRI conditional. In addition, MicroPort® CRM is currently developing a sub-cutaneous ICD (S-ICD) and a leadless pacemaker. The company is pursuing the development of further innovative therapies in the field of Heart Failure, in particular with the Axone project for the delivery of Cardiac Resynchronization Therapy (CRT). The market introduction of these products will provide an additional growth inflection point for the CRM franchise.

Mr. Benoit Clinchamps, President of MicroPort® CRM said: “MicroPort® CRM continues to grow its global revenue and advance its product pipeline to bring the best CRM technologies to treat patients affected by heart arrhythmias worldwide. We are excited about the growth opportunities that can be accessed in the next few years through this investment capital.”

About MicroPort CRM

MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort® Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, just outside Paris, France. Through its long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure. Its state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, Santo Domingo, Dominican Republic, and Shanghai, China.

For more information, please refer to www.microport.com

Cision View original content:https://www.prnewswire.com/news-releases/microport-cardiac-rhythm-management-business-announces-us150-million-series-c-investment-301341782.html

SOURCE MicroPort

Company Codes: HongKong:0853

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/microport-cardiac-rhythm-management-business-announces-us-150-million-series-c-investment/?s=93

Continue Reading

Medical Devices

Soundbite Medical Solutions Announces Issuance of a Fourth U.S. Patent Further Expanding Coverage of its Core Technology

Published

on

The patent is directed to a general system comprising a shock wave generator connected to a mechanical waveguide, for the treatment of lesions in blood vessels. It protects the novel Soundbite system architecture, which is used in all products of the company’s burgeoning portfolio.

The patent is expected to expire in December 2036 and will continue to provide key intellectual property protection for the Company’s technology platform.

This is the fourth US patent to be issued around the approved Soundbite technology. Soundbite continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its patent protection in key markets throughout the world.

“The strength of our patent portfolio is a testament to our highly talented engineering team. The pursuit of excellence in serving our patients begins with medical devices that are unique, differentiated and of the highest quality. Protecting that work and preserving value will establish Soundbite as a leader in its field,” said Lori Chmura, President & CEO of Soundbite.

The SoundBite® Crossing System – Peripheral (SCS-P) consists of the reusable SoundBite® Console, a single-use sterile SoundBite® Active Wire, and their respective accessories. SCS-P leverages Soundbite’s proprietary method to produce and safely deliver shock waves via guidewire platforms to selectively “micro- jackhammer” through calcified lesions.

High calcium burden is present in up to 50% of PAD patients with severe claudication and in >65% of patients with CLI, especially in difficult to treat below-the-knee disease. CTOs are encountered in up to 50% of PAD and CLI patients. CLI is associated with a high risk of lower limb amputation estimated in 10%–40% of patients at 6 months, especially in non-treatable patients.

About Soundbite Medical Solutions

Soundbite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of devices to improve and transform the standard of care for treatment of patients suffering from calcified and occlusive cardiovascular disease. www.soundbitemedical.com

For information on Soundbite Medical Solutions, please contact Ashkan Haghighat, PhD ([email protected]), Chief Business Officer, SoundBite Medical Solutions, 2300 Alfred Nobel, Montreal Québec H4S 2A4

Forward-Looking Statements This press release contains forward-looking statements and forward- looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward- looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/soundbite-medical-solutions-announces-issuance-of-a-fourth-u-s-patent-further-expanding-coverage-of-its-core-technology/?s=93

Continue Reading
Esports4 days ago

Teppei Genshin Impact Voice Actor: Who is it?

Esports4 days ago

Who won Minecraft Championships (MCC) 15? | Final Standings and Scores

Esports4 days ago

All ranked mode rewards for Pokémon UNITE: Season 1

Aviation3 days ago

Legendary F-14 Pilot Dale ‘Snort’ Snodgrass Dies In A Tragic Plane Crash

Cleantech4 days ago

Form Energy Reveals Iron-Air 100 Hour Storage Battery

Esports4 days ago

Sakura Arborism Genshin Impact: How to Complete

Esports5 days ago

Here are the results for the PUBG Mobile World Invitational (PMWI) West 2021

watch-live-russias-pirs-module-set-to-depart-space-station-today.jpg
Aerospace2 days ago

Watch live: Russia’s Pirs module set to depart space station today

Esports5 days ago

Here are the results for the PUBG Mobile World Invitational (PMWI) East 2021

Techcrunch4 days ago

This Week in Apps: Clubhouse opens up, Twitter talks bitcoin, Snap sees record quarter

best-gengar-build-in-pokemon-unite.png
Esports4 days ago

Best Gengar build in Pokémon UNITE

Cyber Security5 days ago

Threat Actors are Abusing Argo Workflows to Target Kubernetes

Esports5 days ago

Are there ranked rewards in Pokémon UNITE?

Esports4 days ago

Best Garchomp build in Pokémon UNITE

Cyber Security5 days ago

What Programming Language Should I Learn for CyberSecurity?

Blockchain4 days ago

Canadian Border Town Halts Crypto Mining to Draw Up Regulations

Esports4 days ago

How to unlock Pokémon in Pokémon UNITE, all Unite License costs

AR/VR4 days ago

Warplanes: WW1 Fighters to See Official Oculus Quest Store Launch This Week

AI4 days ago

What is the Freedom Phone and Should You Buy It?

Crowdfunding4 days ago

Calgary, Alberta’s Allied Venture Partners Confirms they’ve Invested $1M+ into Early-Stage Tech Firms

Trending